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Pan-cancer EMT-signature 
identifies RBM47 down-regulation 
during colorectal cancer 
progression
Matjaz Rokavec1, Markus Kaller1, David Horst2,3,4 & Heiko Hermeking1,3,4
Epithelial-mesenchymal transition (EMT) plays an important role in tumor invasion and metastasis. A 
comprehensive, bioinformatics analysis of CCLE and TCGA datasets of seven tumor types allowed us to 
identify a novel pan-cancer EMT-associated gene expression signature consisting of 16 epithelial and 4 
mesenchymal state-associated mRNAs. Among the identified epithelial cell state-associated factors, 
down-regulation of the RBM47 (RNA binding motif protein 47) mRNA displayed the most significant 
association with metastasis and poor survival in multiple cohorts of colorectal cancer (CRC) patients. 
Moreover, decreased RBM47 protein expression was associated with metastasis in a cohort of primary 
CRCs. RBM47 was directly suppressed during EMT induced by IL6-activated STAT3 or ectopic SNAIL and 
SLUG expression via conserved binding motifs of these factors within the RBM47 promoter. Moreover, 
RNAi-mediated down-regulation of RBM47 in CRC lines resulted in increased cell migration, invasion 
and metastases formation. As demonstrated by the example of RBM47, the EMT-associated signature 
characterized here allows to identify biomarkers for predicting clinical outcome of CRC and presumably 
other cancer entities. In addition, our functional analysis of RBM47 shows that the down-regulation of 
RBM47 during CRC progression may promote EMT and metastasis.
Metastasis accounts for over 90% of cancer mortality1. A better understanding of the molecular mechanism 
of metastasis holds the promise of providing biomarkers and therapeutic strategies to overcome this situation. 
During the metastatic process epithelial tumor cells acquire a migratory mesenchymal phenotype, which allows 
them to leave the site of the primary tumor, invade surrounding tissues and migrate to distant organs2, 3. The pro-
cess by which cells switch from an epithelial to a mesenchymal phenotype is known as the epithelial-mesenchymal 
transition (EMT)4. A hallmark of EMT is the loss of the cell-cell adhesion protein E-Cadherin (encoded by the 
CDH1 gene) and gain of the cytoskeletal protein Vimentin (encoded by the VIM gene)5. In recent years, sev-
eral factors that regulate EMT have been identified, with SNAIL (SNAI1), SLUG (SNAI2), TWIST1, ZEB1, and 
ZEB2 representing the core EMT-TFs (EMT-inducing transcription factors) that also mediate EMT during 
development6, 7. These EMT-TFs directly regulate the expression of E-cadherin or Vimentin8. Many additional 
EMT-inducing factors have been implicated in cancer progression and represent potential diagnostic markers 
or targets for cancer therapy6, 9–11. In addition, several EMT-associated gene signatures have been identified12–17. 
Recently, a consensus molecular subtype (CMS) classification was proposed which subdivides CRCs into four 
main groups18. Notably, cancers that belong to the CMS4 subtype, which is associated with high expression of 
mesenchymal genes and low expression of epithelial genes, exhibit the worst prognosis.
However, the link between EMT and tumor progression is far from being completely understood. To iden-
tify novel EMT-associated markers in cancers, we performed a combined bioinformatic analysis of expression 
data from The Cancer Genome Atlas (TCGA)19 and Cancer Cell Line Encyclopedia (CCLE)20 databases. Only 
markers differentially regulated in both, cancer cell lines and primary tumors, were considered for further anal-
ysis. Thereby, we identified a novel pan-cancer EMT-associated gene signature consisting of 16 epithelial and 4 
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mesenchymal state-associated markers. Since the TCGA expression profiles were obtained from whole tumors, 
stromal cells might lead to the false detection of mesenchymal markers indicative of EMT as they show a mark-
edly higher expression in stromal cells than in cancer cells21–23. Because of the problematic nature of mesenchy-
mal tumor markers we focused on the analysis of epithelial markers. We performed an exemplary validation of 
the RNA binding motif protein 47 (RBM47) as an epithelial state-associated factor and found that it is required 
for the maintenance of an epithelial state and the suppression of migration, invasion, and metastasis. Moreover, 
analysis of patient samples showed that down-regulation of RBM47 protein expression represents a potential 
marker for CRC progression.
Figure 1. Bioinformatic analysis of CCLE and TCGA datasets for EMT-associated signatures. (a) Flow 
chart describing the generation of the shared pan-cancer CCLE/TCGA EMT-associated mRNA signature. 
(b) Heatmap of 201 mRNAs that showed significant differences in expression between epithelial-like and 
mesenchymal-like cancer cell lines within the analysed cancer entities (log2 fold change of expression is 
shown; p < 0.05). (c) Heatmap showing Spearman correlation coefficients of 365 epithelial and mesenchymal 
state-associated mRNAs with CDH1 and VIM. Epithelial state-associated mRNAs were defined as mRNAs 
that positively correlate with expression of the epithelial marker CDH1 (r > 0.1) and negatively correlate 
with expression of the mesenchymal marker VIM (r < −0.1) in all indicated TCGA datasets. Mesenchymal 
state-associated mRNAs were defined as mRNAs that negatively correlate with expression of the epithelial 
marker CDH1 (r < −0.1) and positively correlate with expression of the mesenchymal marker VIM (r > 0.1) 
in all indicated TCGA datasets. COAD, colon cancer; BRCA, breast cancer; LUAD, lung cancer; HNSC, 
head&neck squamous cel cancer; PRAD, prostate adenocarcinomas; BLCA, bladder cancer; PAAD, pancreatic 
adenocarcinomas.
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Results
To identify novel putative EMT-associated genes, we performed a combinatorial bioinformatics analysis of 
CCLE and TCGA public databases (Fig. 1a). First, we utilized expression data from the CCLE database20, which 
contains mRNA expression profiles of approximately 1000 cancer cell lines representing 37 cancer entities. We 
grouped cell lines from colorectal, breast, lung, bladder, and pancreatic cancer based on their epithelial/mesen-
chymal characteristics: epithelial-like cell lines (expression of CDH1 more than 10-fold higher than expression of 
VIM) and mesenchymal-like cell lines (expression of VIM more than 10-fold higher than expression of CDH1) 
(Supplemental Fig. S1a; example for CRC cell lines provided). Next, we compared the expression of all mRNAs 
between epithelial-like and mesenchymal-like cancer cell lines (Fig. 1b). 131 mRNAs showed a significantly 
higher expression in epithelial-like cell lines compared to mesenchymal-like cell lines from all analyzed cancer 
entities, whereas 70 mRNAs were significantly lower expressed in epithelial-like cell lines (Fig. 1b, Table 1, and 
Supplemental Data 1). Next, we performed a second screen by using next generation sequencing RNA expression 
data of seven cancer entities from TCGA19. Thereby, we determined which mRNAs present in the TCGA data-
sets show a negative correlation with the mesenchymal marker VIM and positive correlation with the epithelial 
marker CDH1 (epithelial-state associated mRNAs) or positive correlation with the mesenchymal marker VIM 
and negative correlation with the epithelial marker CDH1 (mesenchymal-state associated mRNAs) (Fig. 1c and 
Supplemental Fig. S1b). To identify factors that are generally associated with EMT and therefore presumably 
of functional importance for EMT in the analyzed TCGA datasets, we selected those mRNAs that are shared 
in all analyzed cancer entities and obtained a list of 42 epithelial state-associated mRNAs and 323 mesenchy-
mal state-associated mRNAs (Fig. 1c, Table 1, and Supplemental Data 2). Finally, 16 epithelial state-associated 
mRNAs and 4 mesenchymal state-associated mRNAs were shared between the CCLE and TCGA screens 
(Table 1 and Supplemental Fig. S2). The TCGA expression data was obtained from whole tumors. Therefore, 
stromal cells within tumors might contribute to the overall expression of a gene. This is especially important for 
mesenchymal-state associated genes, which commonly show one or two orders of magnitude higher expression 
in stromal cells than in cancer cells21–23. On contrary, CCLE expression data is derived from cancer cell lines in 
the absence of tumor stroma. This might explain the low concordance between TCGA and CCLE derived mesen-
chymal state-associated mRNAs.
The shared CCLE/TCGA epithelial- and mesenchymal state-associated gene signatures were used to cluster sam-
ples from the TCGA COAD and GSE39582 cohorts in two groups by k-means clustering. In both cohorts, patients 
with high expression of the mesenchymal-like mRNA signature had a worse overall and relapse-free survival 
than patients from the epithelial-associated group (Fig. 2a and b). Comparison of the identified EMT-associated 
signatures with published EMT-signatures showed some overlap (Supplemental Table S1). Comparison with 
the CMS classification system showed lowest expression of the shared TCGA/CCLE epithelial state-associated 
signature in the mesenchymal CMS4 subtype in two independent CRC patient cohorts (Fig. 2c and d), 
whereas the shared TCGA/CCLE mesenchymal state-associated signature showed the highest expression in the 
mesenchymal CMS4 subtype (Fig. 2c and d).
Several of the EMT-associated genes identified here, such as ESRP1 and ESRP2, have well established roles in 
EMT24, 25, indicating that the bioinformatics screen applied here was appropriate for identifying functionally rel-
evant regulators of EMT. Next, we analyzed whether the identified EMT-associated mRNAs associate with nodal 
status and distal metastasis in the TCGA COAD cohort (Table 2). The most significant association with these 
Cancer entity
Number of samples
Number of epithelial 
state-associated mRNAs
Number of mesenchymal 
state-associated mRNAs
CCLE TCGA CCLE TCGA CCLE TCGA
Colon adenocarcinoma 46 462 1311 2212 3247 2864
Breast invasive carcinoma 40 1095 3454 2604 2478 4485
Lung adenocarcinoma 106 515 2954 653 2075 1156
Pancreatic adenocarcinoma 21 178 754 3292 468 5344
Bladder urothelial carcinoma 22 408 969 3787 1815 4156
Prostate adenocarcinoma n.a. 497 n.a. 2888 n.a. 3945
Head&Neck squamous cell cancer n.a. 303 n.a. 2077 n.a. 4140
Shared EMT-associated mRNAs identified in 
all analyzed cancer types 131 42 70 323
Shared CCLE/TCGA EMT-associated genes 16 4
Table 1. Identification of mRNAs associated with epithelial- or mesenchymal-state as determined by analysis of 
CCLE and TCGA datasets derived from indicated cancer entities. In the CCLE screen, epithelial-state associated 
mRNAs were defined as mRNAs that showed a significantly higher expression in epithelial-like cancer cell lines 
compared with mesenchymal-like cell lines. Mesenchymal-state associated mRNAs were defined as mRNAs 
that showed a significantly higher expression in mesenchymal-like cancer cell lines compared with epithelial-
like cell lines. Significance was calculated by a Student’s t-test (p < 0.05 was considered significant). n.a., not 
analyzed. In the TCGA screen, epithelial-state associated mRNAs were defined as mRNAs that positively 
correlated with expression of the epithelial marker CDH1 (r > 0.1) and negatively correlated with expression of 
the mesenchymal marker VIM (r < −0.1). Mesenchymal-state associated mRNAs were defined as mRNAs that 
negatively correlated with expression of the epithelial marker CDH1 (r < −0.1) and positively correlated with 
expression of the mesenchymal marker VIM (r > 0.1).
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clinical parameters was observed for the RBM47 mRNA, encoding the RNA binding motif 47. Notably, decreased 
expression of the RBM47 mRNA was also significantly associated with presence of distal metastases and increased 
nodal status in the TCGA COAD cohort (Fig. 3a). Moreover, low RBM47 expression was significantly associated 
with poor overall and relapse free survival in TCGA COAD and five additional CRC patient cohorts (Fig. 3b–g), 
Decreased expression of RBM47 was also significantly associated with poor overall and relapse free survival in 
the TCGA pan-cancer dataset, which encompasses expression profiles of more than 8400 cancer patients from 30 
Figure 2. EMT-associated mRNA signatures are associated with survival in colon cancer patients. (a,b) 
Associations of epithelial state (epi) and mesenchymal state (mes) associated groups of samples with survival 
in TCGA COAD (a) and the GSE39582 datasets (b) (epi and mes groups of samples were defined by K-means 
clustering based on expression of the shared CCLE/TCGA epithelial state- or mesenchymal state-associated 
mRNAs. (c,d) Association of the shared TCGA/CCLE epithelial state- and mesenchymal state-associated 
mRNA signatures with the consensus molecular subtypes (CMS) of colorectal cancer in TCGA (c) and 
GSE39582 datasets (d).
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different entities (Supplemental Fig. S3). Finally, the expression of RBM47 was lowest in the mesenchymal CMS4 
subtype in two independent CRC patient cohorts (Fig. 3h).
Next we determined the expression of RBM47 protein in a matched case control cohort of primary CRCs with 
(n = 43) and without (n = 43) liver metastasis (Supplemental Table S2). Patients with liver metastases expressed 
lower levels of RBM47 in primary CRCs (Fig. 4a), suggesting that loss of RBM47 may promote metastasis. 
Additionally, significantly more patients with positive nodal status showed low RBM47 expression when com-
pared to patients with nodal status N0 (Fig. 4a). Interestingly, the expression of RBM47 mRNA was also lower in 
CRC tumors when compared with adjacent normal colonic tissue in samples from TCGA COAD cohort (Fig. 4b). 
Likewise, immuno-histochemical analysis of 31 CRC samples exhibiting adjacent normal mucosa showed that 
in the majority of cases RBM47 protein expression was higher in normal colonic mucosa than in the adjacent 
tumor tissue (see representative example in Fig. 4c and Supplemental Table S3). In line with these results obtained 
in patient derived samples the expression of RBM47 was elevated in epithelial-like cell lines and decreased in 
mesenchymal-like cell lines derived from colorectal, breast, and prostate cancer (Fig. 4d). The epithelial-like or 
mesenchymal-like phenotype of the cell lines analyzed here has been determined previously26. Taken together, 
these results demonstrate that down-regulation RBM47 is highly associated with tumor progression and EMT.
In order to identify up-stream regulators and oncogenic signaling pathways that may cause the observed 
down-regulation of RBM47 in mesenchymal-like cancer cells during tumor progression, we analyzed RBM47 
expression after experimental induction of EMT in CRC cell lines. We have previously shown that treatment 
of epithelial-like DLD1 CRC cells with interleukin-6 (IL-6) induces EMT26. Importantly, the tumor microen-
vironment as well as tumor cells are known to produce IL-6, which enhances tumor progression27, 28. Notably, 
expression of RBM47 mRNA was repressed in DLD1 and HT29 CRC cells upon treatment with IL-6 for 72 hours 
(Fig. 5a and b). Also on the protein level RBM47 was repressed by IL-6 treatment which coincided with acti-
vation of the STAT3 transcription factor (Fig. 5c). Inspection of the RBM47 promoter region revealed two 
potential binding sites for STAT3, 107 (BDS1) and 154 (BDS2) base pairs (bp) upstream of the TSS (transcrip-
tional start site) (Fig. 5d). Indeed, we could verify the binding of STAT3 to both sites by quantitative chroma-
tin immune-precipitation (qChIP): STAT3 binding was enriched at both predicted binding sites in IL-6 treated 
DLD-1 cells, whereas no significant enrichment was observed in the absence of IL-6 (Fig. 5e). Therefore, RBM47 
expression is under direct, negative control of the IL-6/IL-6R/STAT3 pathway.
When inspecting the RBM47 promoter we also noticed two adjacent canonical SNAIL binding sites 357 bp 
and 366 bp upstream of the TSS (Fig. 5d). Therefore, we analyzed whether ectopic expression of SNAIL or 
SLUG, which represent canonical EMT-TFs, suppresses RBM47. Indeed, activation of conditional SNAIL and 
SLUG alleles suppressed expression of RBM47 at the mRNA and protein levels in DLD1 CRC cells (Fig. 6a–d). 
Ectopic expression of SNAIL or SLUG resulted in morphologic changes characteristic for EMT: A tightly packed, 
cobble-stone like growth pattern converted into a scattered pattern with cells adopting a spindle-like shape 
(Fig. 6e). Next, we analyzed the binding of SNAIL to the RBM47 promoter in SW480 CRC cells, which express 
high levels of SNAIL11. qChIP analysis showed an enrichment of SNAIL at the potential SNAIL binding sites in 
the RBM47 promoter (Fig. 6f). Therefore, RBM47 is also repressed by EMT-TFs, which are up-regulated in cancer 
cells during tumor progression and mediate EMT, thereby promoting invasion and presumably metastasis.
Shared TCGA/CCLE 
epithelial state-
associated mRNAs
Fold change 
M0/M1
Fold change 
N0/N+
Shared TCGA/CCLE 
mesenchymal state-
associated mRNAs
Fold change 
M0/M1
Fold change 
N0/N+
AFTPH 1.04 1.01 LGALS1 1.35* 1.23
CDH1 1 1.04 P4HA3 1.3 1.34*
CDS1 0.89* 0.90** UROD 0.95 1.03
EPCAM 1.02 1.05 VIM 1.41* 1.33*
ESRP1 1.02 1.02
ESRP2 1.04 1.00
FA2H 0.93 1.02
HOOK1 0.94 0.91*
LNX1 1.00 1.06
MAP7 1.01 0.94
MAPK13 1.03 1.06
MARVELD2 1.03 0.99
MARVELD3 0.88* 1.00
MYO5B 0.90* 0.92*
MYO5C 0.83** 0.85***
RBM47 0.84*** 0.89***
Table 2. Shared TCGA/CCLE epithelial state- and mesenchymal state-associated mRNAs and their 
associations with distant metastasis and nodal status in the TCGA COAD cohort. Fold change: average 
expression of indicated mRNAs in primary tumors from patients without distant metastases (M0) or negative 
nodal status (N0) divided by average expression of indicated mRNAs in primary tumors from patients with 
distant metastases (M1) or positive nodal status (N+). *P < 0.05; **P < 0.01; ***P < 0.001.
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To investigate whether the down-regulation of RBM47 induces EMT, tumor invasion, and metastasis, RBM47 
was silenced by RBM47-specific siRNAs in DLD1, HCT15, and HT29 CRC cell lines. In HCT15 and partially in 
DLD1 cells suppression of RBM47 resulted in a transition from an epithelial to a mesenchymal morphology: tightly 
packed, cobble-stone like cells became spindle-shaped cells with a scattered growth pattern, whereas in HT29 
cells no change in morphology was observed (Fig. 7a). Furthermore, silencing of RBM47 in DLD1, HT29, and 
HCT15 CRC cells resulted in repression of the epithelial-associated mRNAs E-cadherin (CDH1), OCLN, CLDN1, 
CLDN3, and ZO-1, as well as induction of the EMT-inducer SNAIL in DLD1 and HCT15 cells (Fig. 7b and c). 
Figure 3. Low expression of RBM47 mRNA is associated with metastasis, nodal status, and poor survival in 
CRC patients. (a) Association of RBM47 mRNA expression with metastasis (right) and nodal status (left) in the 
TCGA COAD dataset. (b) Association of RBM47 mRNA expression with overall and relapse free survival in the 
TCGA COAD dataset. (c–g) Associations of RBM47 mRNA expression with relapse free survival in indicated 
CRC dataset. (h) Association of RBM47 mRNA expression with the consensus molecular subtypes (CMS) of 
colorectal cancer in TCGA and GSE39582 datasets.
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The lack of SNAIL induction in HT29 cells might explain the absence of changes in cell morphology of these cells 
after RBM47 knockdown. EMT has been previously associated with increased cancer cell migration, invasion and 
metastasis7. Accordingly, siRNA-mediated silencing of RBM47 in DLD1 and HT29 cells increased cell migration 
in wound healing assays and invasion in modified Boyden chamber assays (Fig. 7d and e). Finally, DLD1-luc2 
cells transfected with RBM47-specific siRNAs formed lung metastases when injected into tail veins of immune 
compromised mice, whereas no metastases formation was observed with non-invasive imaging when DLD1-luc2 
cells transfected with control siRNAs were injected (Fig. 8a and b). After resection of the lungs eight weeks after 
Figure 4. Low expression of RBM47 protein is associated with metastasis and positive nodal status in CRC 
patients (a) Association of RBM47 protein expression with liver metastasis (M1) and nodal metastasis (N+) in 
the M0/M1 patient collection (N = 86). Left panel: representative IHC staining results of patient samples with 
staining scores. Right panel: quantification of IHC staining and association with metastasis (M0 – no metastases 
present, M1 – liver metastases present) and nodal status (N0 – no tumor cells present in lymph nodes, N+ - 
tumor cells present in lymph nodes). The scale bar in low magnification images (upper part) represents 100 μm 
and the bar in high magnification images (lower part) represents 50 μm. (b) Expression of RBM47 mRNA in 
normal colonic tissue and colon tumors in the TCGA COAD dataset. In the left panel expression of RBM47 in 
paired samples from the same patient are shown and in the right panel all samples are shown. (c) Exemplary 
IHC results showing expression of RBM47 protein in a colon cancer (red arrow) and adjacent normal colonic 
mucosa (green arrow). The scale bar represents 100 μm. (d) Immunoblot analysis of RBM47 expression in a 
cell line panel consisting of epithelial-like (E) and mesenchymal-like (M) colorectal (CRC), breast (BC), and 
prostate (PC) cancer cell lines.
www.nature.com/scientificreports/
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injection, macroscopically visible metastases were detectable in mice, which had received RBM47-specific siRNA 
treated cells, whereas mice injected with cells treated with control siRNA did not show any visible metastases 
(Fig. 8c). Haematoxylin and eosin (H&E) staining revealed the presence of metastatic nodules in resected lungs 
of mice injected with cells transfected with RBM47-specific siRNAs, whereas no metastases were detectable in 
lungs of mice injected with cells transfected with control siRNAs (Fig. 8d and e). Taken together, these results 
demonstrate that the loss of RBM47 induces EMT and promotes migration, invasion, and metastases formation 
of CRC cells (for a summarizing model see Fig. 8f).
Figure 5. Direct suppression of RBM47 by IL-6 activated STAT3. (a and b) Expression of RBM47 mRNA in 
(a) DLD1 or (b) HT29 CRC cells after treatment with IL-6 (20 ng/ml) or vehicle for 72 hours. (c) Western blot 
analysis of indicated proteins in DLD1 cells after exposure to IL-6 (20 ng/ml) for the indicated periods. (d) Map 
of the human RBM47 promoter region with the indicated conserved STAT3 and SNAIL binding sites. Filled 
rectangles represent the binding sites. TF binding sequence motifs are indicated by grey shadowing. Their 
conservation between species is indicated by asterisks. The arrow indicates the TSS, // represent additional, not 
shown sequences between the BDS. (e) qChIP analysis of STAT3 occupancy at the RBM47 promoter and, as a 
control, the acetylcholine receptor (ACHR) locus in DLD1 cells treated with vehicle or IL-6 for 20 minutes. In 
a,b, and e mean values ± SD (n = 3) are provided with *P < 0.05; **P < 0.01; ***P < 0.001.
www.nature.com/scientificreports/
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Discussion
By utilizing expression data from online cancer databases, we performed a bioinformatic screen to identify novel 
EMT-associated mRNA markers. Thereby, we identified a novel pan-cancer EMT-associated signature. The mark-
ers identified by analysis of the CCLE cancer cell line data clearly reflect cancer-associated EMT, since they are 
derived from cancer cells only. However, in TCGA expression profiles, which are derived from bulk tumors, 
mesenchymal state-associated mRNAs may also be derived from stromal cells. Since mesenchymal markers are 
expressed up to 10 fold higher in stromal cells, even a small fraction of stromal cells can generate false positive 
mesenchymal tumor markers that may be misinterpreted as indicating EMT of tumor cells. However, epithe-
lial state-associated mRNAs are predominantly expressed by cancer cells and thus varying fractions of stromal 
components will not affect detection of their expression21–23. In this study we therefore focused on epithelial 
state-associated mRNAs, which are down-regulated in CRCs and in CRC cell lines that had undergone EMT. 
Several of the identified epithelial state-associated mRNAs, such as EPCAM, ESRP1, and ESRP2, have well estab-
lished roles in EMT24, 25, 29 indicating that the bioinformatics approach used here was appropriate. However, we 
Figure 6. Direct suppression of RBM47 by the EMT-TFs SNAIL and SLUG. (a) qPCR analysis of RBM47 
mRNA and (b) Western blot analysis of the indicated proteins in DLD1 cell pools harboring pRTR/SNAIL 
plasmids. In (a) cells were treated with DOX or vehicle for 72 hours, in (b) with DOX for the indicated periods. 
(c and d) as in (a) and (b) but using DLD1 cell pools harboring pRTR/SLUG plasmids. (e) Phase contrast 
microscopy of the DLD-pRTR/SNAIL and DLD-pRTR/SLUG cell lines treated with vehicle or DOX for 
48 hours. Scale bars represent 50 μm. (f) qChIP analysis of SNAIL occupancy at the RBM47 promoter and, as 
a control, the acetylcholine receptor (ACHR) locus in SW480 cells. In a, c, and f mean values ± SD (n = 3) are 
provided. *P < 0.05; **P < 0.01; ***P < 0.001.
www.nature.com/scientificreports/
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Figure 7. Inhibition of RBM47 induces EMT, cell migration and invasion. (a) Phase contrast microscopy of the 
indicated CRC cell lines transfected with control or RBM47-specific siRNA. Scale bars represent 100 μm. (b) Western 
blot analysis of the indicated proteins in CRC cell lines transfected with control or RBM47-specific siRNA for 72 h. 
(c) qPCR analysis of the indicated mRNAs in the indicated CRC cell lines transfected with control or RBM47-specific 
siRNA for 72 h. (d) Wound healing assay of the indicated CRC cell lines transfected with control or RBM47-specific 
siRNA 48 hours before a scratch was generated. (Upper panels) Representative photographs of the initial wound 
area and the same area 24 hours later. (Lower panels) Quantification of wound closures: The width of scratches in 
2 independent wells was analyzed for each state. Results represent the average (%) of wound closure. (e) Relative 
invasion of indicated CRC cells in matrigel-coated Boyden chambers transfected with control or RBM47-specific 
siRNA for 48 hours. In c, d, and e mean values ± SD (n = 3) are provided. *P < 0.05; **P < 0.01; *** P < 0.001.
www.nature.com/scientificreports/
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also identified differential expression of genes, such as CDS1, MAP7, and RBM47, for which an involvement in 
EMT was relatively unknown. Because of its strong association with positive nodal status and distant metastasis 
we focused on RBM47 in order to functionally validate an exemplary candidate obtained by this approach. By ana-
lyzing mouse models and patient collections we could show that down-regulation of RBM47 promotes colorectal 
cancer metastasis and is associated with poor survival of CRC patients. In support of our findings, RBM47 was 
previously reported as one of the genes down-regulated genes in the mesenchymal CRC sub-type associated 
with poor survival30. Furthermore, we showed that RBM47 is suppressed during CRC-associated EMT that was 
triggered by several different stimuli. Moreover, suppression of RBM47 enhanced CRC cell migration, invasion, 
and metastasis, suggesting that inactivation of RBM47 function promotes CRC progression. We also showed that 
Figure 8. Inhibition of RBM47 induces metastasis. Formation of lung metastases after tail-vein injection of 
DLD-1–Luc2 cells transfected with control or RBM47-specific siRNA. (a) Representative images of luciferase 
signals after D-luciferin injection at the indicated time points after xenografting. (b) Weekly measurements 
of total photon flux. Results are the mean ± SD (n = 5). **P < 0.01. (c) Representative lungs 8 weeks after tail 
vein injection. (d) H&E staining of lung tissue. Scale bars represent 500 μm. (e) Number of metastatic nodules 
in lungs 8 weeks after tail vein injection of the indicated DLD1 cells into mice (n = 5). (f) Model of regulation 
of RBM47 expression and its downstream targets, which presumably mediate its effects on EMT and cancer 
progression.
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elevated expression of RBM47 is strongly associated with the epithelial cell state in multiple cancer types, whereas 
its expression is strongly decreased in mesenchymal-like tumor cells. This may be explained by direct repression 
of RBM47 via the EMT-inducers STAT3 and SNAIL, which are generally activated in mesenchymal-like, invasive 
cancer cells. While this manuscript was in preparation Sakurai et al. showed that expression of RBM47 is also 
repressed by TGF-β via direct binding of Smad3 to the RBM47 promoter31. Interestingly, CRC cell lines with an 
intact TGF-β receptor, such as HCT15, undergo EMT after exposure to TGF-β32, whereas normal epithelial cells 
display a growth arrest. In this context it is noteworthy that the tumor microenvironment plays an important 
role in tumor-associated EMT, invasion, and metastasis. For example, IL-6 and TGF-β are produced and secreted 
by stromal cells of the tumor microenvironment28. Since both cytokines lead to repression of RBM47 in tumor 
cells, this might represent an important mechanism as to how the tumor microenvironment promotes cancer 
progression.
Interestingly, comparison of the CRC cell line pair SW480/SW620, which both originate from the same patient 
– SW480 from the primary tumor and SW620 from a lymph node metastasis – showed an elevated expression of 
RBM47 in the SW620 cells. This finding might be explained by a reversion of EMT during metastasis. It has been 
suggested that cancer cells first switch from epithelial- to mesenchymal-like cell state (EMT) to leave the primary 
tumor, and then switch back to an epithelial-like state (mesenchymal to epithelial transition (MET)) to colonize 
distant organs and form metastases33–35. Accordingly, based on CCLE data and our previous findings, expression 
of the epithelial marker E-cadherin is higher in SW620 cells than in SW480 cells26. Therefore, re-expression of 
RBM47 after extravasation might promote metastatic colonization.
The tail-vein injection model of lung metastasis used here does not recapitulate the whole metastatic process, 
but rather the late stages - extravasation and colonization36. However, it has been shown that EMT promotes 
extravasation after tail vein injection of tumor cells33, which may explain the formation of metastases in mice 
injected with DLD1 CRC cells treated with RBM47-specific siRNAs. After extravasation, which is a relatively rapid 
process37, cancer cells remain in the lungs for several weeks. By this time the siRNAs are presumably too diluted in 
order to repress RBM47. The resulting re-expression of RBM47 might promote the formation of macro-metastases, 
since the epithelial state is known to promote metastatic colonization by enhancing proliferation.
Potential mechanisms of tumor suppression by RBM47 have been suggested in recent studies (see also Fig. 8f). 
RBM47 is a RNA binding protein that binds predominantly to introns and 3′-UTRs of its target mRNAs and 
regulates their stability38: RBM47 binds to ∼2500 mRNAs in human breast cancer cells. One of these transcripts 
is the DKK1/Dickkopf1 mRNA, which encodes an inhibitor of Wnt signaling. RBM47 stabilizes DKK1 mRNA and 
thereby inhibits Wnt activity. This effect could also explain how RBM47 mediates suppression of breast cancer 
metastases38. In addition, the regulation of the Wnt pathway by RBM47 was shown to play an important role 
during zebrafish development39. Since Wnt signaling has a crucial role in CRC metastasis, the Wnt-suppressing 
function of RBM47 via stabilization of DKK1 may suppress CRC progression. In addition, RBM47 regulates RNA 
editing40 and splicing41, 42. Moreover, RBM47 was shown to suppress lung cancer growth through inhibition of 
Nrf2 activity31. RBM47 directly binds to mRNAs of Nrf2 inhibitors Cullin3 and Keap1 thereby up-regulating their 
expression. Given its diverse functions, the tumor suppressive properties of RBM47 may be mediated by several 
different targets and/or mechanisms.
Taken together, our results show that down-regulation of RBM47 is associated with and functionally impor-
tant for CRC progression. Therefore, detection of RBM47 down-regulation may serve as a new prognostic marker 
for CRC and might represent an important diagnostic option to identify patients with poor prognosis in the 
future. In addition, our results suggest that restoration of RBM47 function represents a potential therapeutic 
strategy for treatment of metastatic CRC.
Materials and Methods
Cell lines, cell culture and reagents. Colorectal cancer (SW480, SW620, Caco-2), breast cancer (MCF7, 
MDA-MB-231), and prostate cancer (LNCaP, PC-3) cell lines were maintained in Dulbecco’s Modified Eagles 
Medium (DMEM, Invitrogen) containing 10% fetal bovine serum (FBS, Invitrogen). The colorectal cancer cell 
lines HCT-15, HT29, LS174T, HCT116 and DLD-1 were maintained in McCoy’s 5 A Medium (Invitrogen) con-
taining 10% FBS. All cells were cultivated in presence of 100 units/ml penicillin and 0.1 mg/ml streptomycin. 
SiRNAs (Ambion silencer siRNA: negative control (ID#4611) and RBM47 (ID#s29090) were transfected at a 
final concentration of 10 nM using HiPerfect transfection reagent (Qiagen). IL-6 (Immunotools) was dissolved in 
water and used at a final concentration of 20 ng/ml.
Conditional expression of SNAIL and SLUG alleles in cell pools. Stable DLD1/pRTR-SNAIL cell 
pools were described previously32. The SLUG cDNA was amplified by PCR from pcDNA-SLUG (a kind gift from 
Kou-Juey Wu, Institute of Biochemistry & Molecular Biology, National Yang-Ming University, Taiwan), verified 
by sequencing and cloned into the pRTR vector. Stable DLD1/pRTR cell pools were obtained transfection of 
DLD-1 cells with pRTR plasmids using FuGene reagent (Roche). After 24 hours, cells were transferred into media 
containing 4 µg/ml Puromycin for one week. Homogeneity of the derived cell pools was tested by addition of 
100 ng/ml DOX for 48 hours and evaluation of GFP expression by fluorescence microscopy.
RNA isolation and quantitative real-time PCR (qPCR). Total RNA was isolated using the Total 
RNA Isolation Kit (Roche) according to manufacturer’s instructions. cDNA was generated from 1 µg total RNA 
per sample using the Verso cDNA synthesis kit (Thermo scientific). Quantitative real-time PCR (qPCR) was 
performed by using the LightCycler 480 (Roche) and the Fast SYBR Green Master Mix (Applied Biosystems). 
Expression was normalized using detection of GAPDH using the ΔΔCt method43. Results are represented as fold 
induction of the treated/transfected condition compared with the control condition Experiments were performed 
in triplicates. The sequences of oligonucleotides used as qPCR primers are listed in Supplemental Table S4.
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Chromatin immunoprecipitation (ChIP) assay. Cross-linking of cells was performed with 1% formalde-
hyde (Merck) and terminated after 5 minutes by addition of glycine at a final concentration of 0.125 M. Cells were 
harvested with SDS buffer (50 mM Tris pH 8.1, 0.5% SDS, 100 mM NaCl, 5 mM EDTA) and after pelleting resus-
pended in IP buffer (2 parts of SDS buffer and 1 part Triton dilution buffer (100 mM Tris-HCl pH 8.6, 100 mM 
NaCl, 5 mM EDTA, pH 8.0, 0.2% NaN3, 5.0% Triton X-100). Chromatin was sheered by 8 sonication cycles (HTU 
SONI 130, G. Heinemann) to generate DNA fragments with an average size of 700 bp for qChIP. Preclearing and 
incubation with polyclonal STAT3 antibody (sc-482, Santa Cruz), SNAIL antibody (#AF3639, R&D systems), or 
IgG control (#R-5506, Sigma or #AB-108-C, R&D systems) for 16 hours was performed as previously described44. 
Washing and reversal of cross-linking was performed as described45. ChIP-DNA was analyzed by qPCR and the 
enrichment was expressed as % input. Experiments were performed in triplicates. The sequences of oligonucleo-
tides used as qChIP primers are listed in Supplemental Table S5.
Western blot analysis and antibodies. Cell-lysates were collected in RIPA lysis buffer (50 mM Tris/
HCl, pH 8.0, 250 mM NaCl, 1% NP40, 0.5% (w/v) sodium deoxycholate, 0.1% sodium dodecylsulfate, complete 
mini protease and phosphatase inhibitors (Roche). Lysates were sonicated and centrifuged for 15 min at 4 °C. 
Per lane 30–60 µg of whole cell lysate was separated on 10% SDS-acrylamide gels and transferred on Immobilon 
PVDF membranes (Millipore). For immunodetection membranes were incubated with antibodies listed in 
Supplemental Table S6. Signals from horse-radish-peroxidase (HRP) - coupled secondary antibodies were gen-
erated by enhanced chemiluminescence (Millipore) and recorded with a CCD camera (440CF imaging system, 
Eastman Kodak Co.). Intensities of protein expression signals were quantified using densitometric analysis with 
the Kodak Molecular Imaging Software v5.0.1.27.
Boyden-chamber invasion assay. To analyse invasion, cell inserts (8.0 µm pore size membrane; 
Corning) were first coated with Matrigel (BD Bioscience) at a dilution of 3.3 ng/ml in medium without serum. 
Subsequently, 5 × 104 cells, previously deprived of serum (0.1%) for 24 hours, were seeded on the Matrigel in the 
upper chamber in serum free medium. As chemo-attractant 20% FBS was placed in the lower chamber. After 
48 hours, non-motile cells at the top of the filter were removed and the cells in the bottom chamber were fixed 
with methanol and stained with DAPI and counted using immunofluorescence microscopy. Results represent 
the average number of cells in five fields per membrane in triplicate inserts. Experiments were performed in 
triplicates.
Wound healing assay. Cells were cultured until they reached complete confluence. Mitomycin C [10 
ng/ml] was added two hours before generating a scratch using a pipette tip. After washing twice with HBSS to 
remove Mitomycin C and detached cells, medium was added. Images were captured on an Axiovert Observer 
Z.1 microscope connected to an AxioCam MRm camera using the Axiovision software (Zeiss) at the respective 
time-points. Experiments were performed in triplicates.
Metastases formation in a xenograft mouse model. DLD-1 cells stably expressing Luc2 were gen-
erated as described previously11. 4 × 106/0.2 ml Luciferase tagged cells were injected into the lateral tail vein of 
NOD/SCID mice using 25-gauge needles. In weekly intervals anesthetized mice were injected intraperitoneal 
with D-luciferin (150 mg/kg) and imaged 10 minutes after injection using the IVIS Illumina System (Caliper 
Life Sciences). The acquisition time was 2 minutes. 8 weeks after tail vein injection, mice were sacrificed and 
examined for lung metastases. For H&E stainings, lungs were fixed with 4% paraformaldehyde and 3 μm sections 
were stained with haematoxylin and eosin. All studies involving mice were conducted with approval by the local 
Animal Experimentation Committee (Regierung of Oberbayern). All experiments were performed in accordance 
with relevant guidelines and regulations.
Clinical samples and immunohistochemistry. RBM47 expression was evaluated using formalin-fixed, 
paraffin-embedded (FFPE) colon cancer samples of 86 patients who underwent surgical tumor resection at 
the Ludwig-Maximilians University of Munich (LMU) between 1994 and 2005. Follow-up data were recorded 
by the tumor registry Munich. All tumors were located on the right side of the colon. Half of the patients had 
colon cancers with synchronous liver metastases, where metastasis was diagnosed by clinical imaging or liver 
biopsy. Controls consisted of colon cancer patients without distant metastases at the time of diagnosis and with 
a disease-free survival of at least 5 years after primary surgical resection. The samples of cases and controls 
were matched by tumor grade (according to WHO 2000), T-classification (according to TNM Classification of 
Malignant Tumors 2009), and tumor localization, resulting in 43 matched pairs. Tissue microarrays (TMAs) 
were generated with 6 representative 1 mm cores of each case. 5 µm TMA sections were prepared, deparaffin-
ized, and stained with anti-RBM47 (Abcam ab167164) rabbit monoclonal antibody on a Ventana Benchmark XT 
Autostainer with UltraView Universal DAB and alkaline phosphatase detection kits (Ventana Medical Systems). 
RBM47 expression was scored semi-quantitatively, ranging from complete absence (score 0), weak (score 1), 
moderate (score 2), or strong expression (score 3). The difference in RBM47 expression between patients with-
out distant metastases was analyzed using the Chi-square test. The study was performed with permission of the 
ethics committee of the Medical Faculty of the LMU. All analyses were performed in accordance with relevant 
guidelines and regulations.
Analysis of expression data from public databases. TCGA expression and clinical data was obtained 
from the TCGA data portal (tcga-data.nci.nih.gov/tcga/tcgaDownload.jsp)19 and the UCSC cancer browser 
(https://genome-cancer.ucsc.edu)46. The RNA-Seq by Expectation-Maximization (RSEM) normalized expression 
values from the Illumina RNASeqV2 (genes) datasets were used. Expression data of cancer cell lines was obtained 
www.nature.com/scientificreports/
1 4Scientific RepoRts | 7: 4687  | DOI:10.1038/s41598-017-04234-2
from The Cancer Cell line Encyclopedia (http://www.broadinstitute.org/ccle/home)20. The quantile normalized 
robust multi-array average (RMA) values assessed by the Affymetrix U133 PLUS 2.0 array were used. The CMS 
classification of TCGA and GSE39582 samples was obtained from Synapse (www.synapse.org), #syn2623706. 
Expression and clinical data of GSE39582, GSE37892, GSE24551, GSE17536, and GSE33113 datasets was down-
loaded from NCBI GEO (www.ncbi.nlm.nih.gov/geo).
Statistical analysis. For CCLE analyses, cell lines from colorectal, breast, lung, bladder, and pancre-
atic cancer were first grouped according to their epithelial/mesenchymal characteristics: epithelial-like cell 
lines (expression of CDH1 more than 10-fold higher than expression of VIM) and mesenchymal-like cell lines 
(expression of VIM more than 10-fold higher than expression of CDH1). Next, the difference in expression of 
all mRNAs between epithelial-like and mesenchymal-like cancer cell lines was analyzed by a Student’s t-test 
(p < 0.05 was considered significant). For analyses of TCGA data, the expression of each mRNA was correlated 
with the expression of CDH1 and VIM in seven cancer entities using the Spearman non-parametric correlation 
coefficient. Epithelial state-associated mRNAs were defined as mRNAs that positively correlate with expression 
of the epithelial marker CDH1 (r > 0.1) and negatively correlate with expression of the mesenchymal marker 
VIM (r < −0.1). Mesenchymal state-associated mRNAs were defined as mRNAs that negatively correlate with 
expression of the epithelial marker CDH1 (r < −0.1) and positively correlate with expression of the mesen-
chymal marker VIM (r > 0.1). Data was analyzed and results visualized using the Multiple Experiment Viewer 
package47. Venn diagrams were designed using Venn Diagram Plotter software (https://omics.pnl.gov/software/
venn-diagram-plotter). Expression of mRNA signatures was calculated as average of z-score normalized expres-
sion of all mRNAs from the signature. The statistics for Kaplan-Meier survival curves was calculated by log-rank 
test. For binary classification of cases (high/low expression), receiver operated characteristics (ROC) curve anal-
ysis was used to determine optimal cut-off values using the Cut-off Finder tool (http://molpath.charite.de/cutoff/
assign.jsp). The classification of TCGA COAD and GSE39582 samples into epithelial- or mesenchymal-associated 
groups in Fig. 2a and b was performed using k-means clustering (Pearson correlation, number of clusters: 2, 
maximum iterations: 50). The association of RBM47 expression with nodal status or metastasis in TCGA data was 
calculated by Student’s t-test. The association of RBM47 protein expression with metastasis was calculated using 
the chi-square test. qPCR and invasion data is expressed as mean ± SD. Differences were analyzed by a two tailed 
Student’s t-test. Differences in total photon flux in xenograft experiments were determined by a paired two tailed 
Student’s t-test. Calculations were performed using Prism5 (Graph Pad Software Inc.) and p-values ≤ 0.05 were 
considered as significant. * ≤ 0.05; ** ≤ 0.01; *** ≤ 0.001.
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